Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced NonCCR5-Tropic HIV-1 Infected Subjects
This study has been completed.
First Posted: December 8, 2004
Last Update Posted: December 7, 2010
Information provided by: